Skip Navigation


Annals of Oncology Advance Access originally published online on June 2, 2008
Annals of Oncology 2008 19(7):1355; doi:10.1093/annonc/mdn290
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
19/7/1355    most recent
mdn290v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Mantovani, G.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mantovani, G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org

letters to the editor

Circulating interleukin-6 as a tumor marker for hepatocellular carcinoma

The first 10% of the full text of this article appears below.

I have read with great interest the paper by Porta et al. [1] on circulating interleukin (IL)-6 as a promising tumor marker for hepatocellular carcinoma (HCC).

I have appreciated the attempt of the authors to put the ‘pleiotropic’ cytokine IL-6 not only in the context of its complex biologic activities but also . . . [Full Text of this Article]

G. Mantovani*

Department of Medical Oncology, University of Cagliari, Italy

* (E-mail: mantovan@medicina.unica.it)


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?